Reshaping the HIV treatment and prevention landscape
Reshaping the
HIV treatment
and prevention
landscape
Mid single digit % sales CAGR 2021-26
Pioneering innovation for treatment and prevention
Dovato and cabotegravir drive growth
Cabotegravir LA portfolio replaces dolutegravir as foundational medicine
Innovative LA pipeline powers revenue renewal beyond dolutegravir
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for
the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards.
LA long acting
81View entire presentation